Encouraging the development and marketing authorization of new drugs has been a highlight in China's reform started in 2015 for improving the drug review and approval system.
Expedited programs have been launched for the Center for Drug Evaluation (CDE) to prioritize the review and accelerate the approval of new drugs with significant clinical value, especially orphan drugs for rare diseases, pediatric drugs, drugs for major infectious diseases, and drugs urgently needed for public health.
Also, China has become more integrated into the international drug regulatory system since joining the ICH in 2017. Thus, China's regulatory environment is improving for overseas new drugs to seek marketing authorization.
With total drug sales scoring 1,558.5 billion yuan (circa 214.9 billion USD) in 2021, China continues attracting drug companies as a considerable pharmaceutical market. To help pharma companies register new drugs in China, this webinar will introduce the regulatory requirements for submitting new drug applications (NDAs) to CDE.
